23:43 , Mar 27, 2019 |  BC Extra  |  Financial News

Gene therapy company Prevail raises $50M series B

Prevail raised $50 million in a series B round to advance its pipeline of gene therapies for neurodegenerative diseases. Existing investors participating in the round included OrbiMed Advisors, Pontifax, RA Capital Management, EcoR1 Capital, Omega...
19:06 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....
22:05 , Jan 3, 2019 |  BC Extra  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Thursday....
18:30 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
20:09 , Nov 8, 2018 |  BC Extra  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
16:29 , Sep 21, 2018 |  BC Week In Review  |  Financial News

Ahead of Phase III mucositis study, Galera raises $150M

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase...
18:17 , Sep 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase III mucositis study, Galera raises $150M

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase...
14:42 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital,...
19:46 , Jun 26, 2018 |  BC Extra  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital,...
18:44 , Mar 9, 2018 |  BioCentury  |  Finance

Genetics prevail

Prevail Therapeutics Inc.’s focus on genetic subpopulations of patients with neurodegenerative diseases led EcoR1 Capital to join the newco’s tranched $75 million series A round. The round’s investors included OrbiMed Advisors, Pontifax Fund, RA Capital...